Amgen’s Teneobio misadventure has taken a $650 million BiTE out of its earnings. The Big Biotech took the hit after stopping a phase 1 trial of the PSMA bispecific it picked up in the $900 million acquisition of Teneobio two years ago.Buying Teneobio gave Amgen control of AMG 340, a PSMAxCD3 bispecific designed to turn […]